CytRx Corporation

Co-discoverer of RNA interference joins board at biopharmaceutical firm

Published in Drug Law Weekly, April 13th, 2004

Craig Mello, PhD, co-discoverer of the revolutionary RNA interference technology (RNAi), also known as "gene silencing," has joined the scientific advisory boards of CytRx Corporation (CYTR) and its subsidiary, Araios, Inc.

Known as a technological innovator in the field of molecular genetics, Mello, of the University of Massachusetts Medical School, along with Andrew Fire, PhD, of Stanford University, is a key inventor on the first approved patent for the use of double stranded RNA for gene silencing, a technology that has come to be known as RNAi

RNAi has already become a groundbreaking tool for drug discovery that allows researchers to rapidly...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-04-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry